AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous blockade of the glycoprotein IIb/IIIa receptor
Number of subjects: 0
Study 12355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive approach
Number of subjects: 0
Study 12355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment duration
Number of subjects: 0
Study 12355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of glycoprotein IIb/IIIa inhibitor
Number of subjects: 0
Study 9801015 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of phospholipid dihomogammalinolenic acid (20:3)
Number of subjects: 323
Study 9801015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake
Number of subjects: 323
Study 9801015 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary intake or serum levels of polyunsaturated fatty acids
Number of subjects: 323
Study 7642758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Spiders Questionnaire (FSQ)
Number of subjects: 338
Study 7642758 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control groups
Number of subjects: 338
Study 7642758 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of FSQ
Number of subjects: 338
Study 2694315 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg/kg of ivermectin
Number of subjects: 198
Study 2694315 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mcg/kg of ivermectin
Number of subjects: 198
Study 2694315 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg/kg of ivermectin
Number of subjects: 198
Study 2694315 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 198
Study 688164 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 1500
Study 31848837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling labels (problem gambling, pathological gambling, gambling disorder, gambling addiction)
Number of subjects: 0
Study 31848837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder
Number of subjects: 0
Study 31848837 — intervention group
Group type: COMPARATOR
Intervention: Depression, obsessive-compulsive disorder, asthma
Number of subjects: 0
Study 31848837 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsive buying disorder
Number of subjects: 0
Study 30990591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobriety incentives
Number of subjects: 229
Study 29630646 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 2 (NGS)
Number of subjects: 24
Study 29630646 — intervention group
Group type: COMPARATOR
Intervention: Procedure 1 (Pre-procedural scan)
Number of subjects: 24
Study 26913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Number of subjects: 0
Study 26913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 0
Study 26913766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25917009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Number of subjects: 41
Study 25917009 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene (SH) control condition combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Number of subjects: 41
Study 22797748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis Health Promotion (HHP) group
Number of subjects: 156
Study 22797748 — intervention group
Group type: COMPARATOR
Intervention: Art Messaging (AM) group
Number of subjects: 156
Study 20940691 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens (Permixon®) 320 mg daily for two months prior to surgery (G1)
Number of subjects: 144
Study 17557211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based pharmacy advisory service
Number of subjects: 500
Study 16637758 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially generated emotions (comedy, bereavement)
Number of subjects: 4
Study 16637758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsocially generated emotions (pizza scenes, wounded bodies)
Number of subjects: 4
Study 16637758 — intervention group
Group type: COMPARATOR
Intervention: Nonsocially generated emotions
Number of subjects: 4
Study 16637758 — intervention group
Group type: COMPARATOR
Intervention: Social/nonsocial dimension
Number of subjects: 4
Study 12907984 — intervention group
Group type: EXPERIMENTAL
Intervention: CosmoPost
Number of subjects: 0
Study 12907984 — intervention group
Group type: EXPERIMENTAL
Intervention: Composipost Aestheti‐Plus
Number of subjects: 0
Study 12907984 — intervention group
Group type: EXPERIMENTAL
Intervention: Composipost Light‐Post
Number of subjects: 0
Study 12907984 — intervention group
Group type: EXPERIMENTAL
Intervention: Para Post Fiber White
Number of subjects: 0
Study 12907984 — intervention group
Group type: COMPARATOR
Intervention: Conventional gold alloy posts (control)
Number of subjects: 0
Study 10715308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirapazamine plus cisplatin (390 mg/m2 infused over 2 hours followed 1 hour later by cisplatin 75 mg/m2 over 1 hour, every 3 weeks for a maximum of eight cycles)
Number of subjects: 446
Study 10715308 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone (75 mg/m2, every 3 weeks for a maximum of eight cycles)
Number of subjects: 446
Study 10369643 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Sequestration (PSQ)
Number of subjects: 60
Study 10369643 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 60
Study 1539786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 72
Study 1539786 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum followed by paracetamol plus dextropropoxyphene orally
Number of subjects: 72
Study 1539786 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 72
Study 3904205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Number of subjects: 76
Study 3904205 — intervention group
Group type: COMPARATOR
Intervention: Radiation treatment alone
Number of subjects: 76
Study 3904205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma therapy with total focal dose of 90-120 Gy
Number of subjects: 76
Study 30430221 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial femoral epicondyle upsliding osteotomy with PS arthroplasty (group A)
Number of subjects: 53
Study 30430221 — intervention group
Group type: COMPARATOR
Intervention: Constrained arthroplasty (group B)
Number of subjects: 53
Study 29175357 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sodium nitrite (1 or 9.6mg)
Number of subjects: 11
Study 29175357 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sodium nitrite (9.6mg)
Number of subjects: 11
Study 29175357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 25648345 — intervention group
Group type: EXPERIMENTAL
Intervention: Block periodization (BP)
Number of subjects: 19
Study 25648345 — intervention group
Group type: COMPARATOR
Intervention: Traditional training organization (TRAD)
Number of subjects: 19
Study 26460661 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-admission cholecystectomy
Number of subjects: 266
Study 26460661 — intervention group
Group type: COMPARATOR
Intervention: Interval cholecystectomy
Number of subjects: 266
Study 23194211 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation with I:E ratio of 1:1
Number of subjects: 56
Study 23194211 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation with I:E ratio of 1:2
Number of subjects: 56
Study 20130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Mobilisation (EM)
Number of subjects: 32
Study 20130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Monitoring (AM)
Number of subjects: 32
Study 20130401 — intervention group
Group type: COMPARATOR
Intervention: Standard Stroke Unit Care
Number of subjects: 32
Study 20130401 — intervention group
Group type: COMPARATOR
Intervention: Combined EM and AM
Number of subjects: 32
Study 18518697 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTBI group (32 patients)
Number of subjects: 80
Study 18518697 — intervention group
Group type: COMPARATOR
Intervention: MTBI group (48 patients)
Number of subjects: 80
Study 18518697 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTBI group (among patients with mild or no extracranial injury)
Number of subjects: 80
Study 18518697 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTBI group (among patients without preinjury ADHD)
Number of subjects: 80
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET after the first cycle of chemotherapy
Number of subjects: 11
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET after the second cycle of chemotherapy
Number of subjects: 11
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET for nonresponding lesions after the first cycle of chemotherapy
Number of subjects: 11
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET for nonresponding lesions after the second cycle of chemotherapy
Number of subjects: 11
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in responders
Number of subjects: 11
Study 16000283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in nonresponders
Number of subjects: 11
Study 12432319 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics pro re nata (as needed)
Number of subjects: 31
Study 12432319 — intervention group
Group type: COMPARATOR
Intervention: Regularly scheduled opioid analgesics
Number of subjects: 31
Study 9872816 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A hypopnea scoring criteria (>= 4% decrease in oxygen saturation)
Number of subjects: 94
Study 9872816 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B hypopnea scoring criteria (either a >= 4% decrease in SaO2 or an arousal)
Number of subjects: 94
Study 8565248 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy (group 1)
Number of subjects: 31
Study 8565248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 31
Study 2963534 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and 5 fluorouracil (MTX‐FU)
Number of subjects: 34
Study 2963534 — intervention group
Group type: COMPARATOR
Intervention: Methyl CCNU, vincristine, FU, and streptozotocin (MOF‐Strep)
Number of subjects: 34
Study 30337757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride releasing flowable resin
Number of subjects: 76
Study 30337757 — intervention group
Group type: COMPARATOR
Intervention: Conventional fissure sealant
Number of subjects: 76
Study 27927736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 0
Study 27927736 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate
Number of subjects: 0
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.10 mg/kg)
Number of subjects: 75
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.15 mg/kg)
Number of subjects: 75
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.20 mg/kg)
Number of subjects: 75
Study 25502841 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 75
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (all doses)
Number of subjects: 75
Study 25502841 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 75
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 75
Study 25502841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam and Midazolam
Number of subjects: 75
Study 23554134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68
Study 21364151 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 162
Study 21364151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 162
Study 21364151 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 162
Study 21364151 — intervention group
Group type: COMPARATOR
Intervention: Angiographic restenosis
Number of subjects: 162
Study 18507183 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial sylvinite speleotherapy
Number of subjects: 120
Study 18507183 — intervention group
Group type: EXPERIMENTAL
Intervention: General chloride sodium baths
Number of subjects: 120
Study 21227735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weekly replacement lenses
Number of subjects: 1432
Study 21227735 — intervention group
Group type: COMPARATOR
Intervention: Monthly replacement lenses
Number of subjects: 1432
Study 21227735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens storage case cleaning frequency
Number of subjects: 1432
Study 21227735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens storage case replacement frequency
Number of subjects: 1432
Study 21227735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens case cleaning method
Number of subjects: 1432
Study 16118078 — intervention group
Group type: EXPERIMENTAL
Intervention: Team instructed physiotherapy (12 sessions of 60 min, two sessions a week, starting between the sixth and eighth postoperative week)
Number of subjects: 139
Study 16118078 — intervention group
Group type: COMPARATOR
Intervention: Team instructed physiotherapy (12 sessions of 60 min, two sessions a week, starting at the 26th postoperative week)
Number of subjects: 139
Study 12390609 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary management program (neurologist and physical therapist intake and discharge, 18 group-supervised exercise therapy sessions, 2 group stress management and relaxation therapy lectures, 1 group dietary lecture, and 2 massage therapy sessions)
Number of subjects: 80
Study 12390609 — intervention group
Group type: COMPARATOR
Intervention: Standard care with the patient's family physician
Number of subjects: 80
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP target < 90 mmHg
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP target < 85 mmHg
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP target < 80 mmHg
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine treatment
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional prescription of beta-blocker
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional prescription of ACE-inhibitor
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effects rate
Number of subjects: 18790
Study 9749162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle edema
Number of subjects: 18790
Study 8156459 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin, 1,500,000 international units, twice per day (IU, bid) for 14 days
Number of subjects: 193
Study 8156459 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (visually identical)
Number of subjects: 193
Study 2459514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg once or twice daily)
Number of subjects: 0
Study 2459514 — intervention group
Group type: COMPARATOR
Intervention: Ritanserin (10 mg twice daily)
Number of subjects: 0
Study 12392830 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 366
Study 12392830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 30091976 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c testing for T2DM
Number of subjects: 400
Study 30091976 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 400
Study 30091976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and BMI as risk factors
Number of subjects: 400
Study 30091976 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical comparison
Number of subjects: 400
Study 26572551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (group sessions)
Number of subjects: 653
Study 26572551 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (group sessions)
Number of subjects: 653
Study 26572551 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cognitive rehabilitation program (individual sessions)
Number of subjects: 653
Study 26572551 — intervention group
Group type: COMPARATOR
Intervention: Usual care (reference group)
Number of subjects: 653
Study 25216143 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed level with the buccal crest (Group 0)
Number of subjects: 30
Study 25216143 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed 1 mm apical to the buccal aspect of the alveolar crest (Group 1)
Number of subjects: 30
Study 25216143 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed 2 mm apical to the buccal aspect of the alveolar crest (Group 2)
Number of subjects: 30
Study 23243973 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin without fluoride (Group A)
Number of subjects: 139
Study 23243973 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin with fluoride (Group B)
Number of subjects: 139
Study 23243973 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis paste without fluoride (Group C)
Number of subjects: 139
Study 21035616 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT-P (11 practitioner-assisted group sessions)
Number of subjects: 159
Study 21035616 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT-S (single instructional workshop followed by self-administration)
Number of subjects: 159
Study 21035616 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT-P
Number of subjects: 159
Study 21035616 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT-S
Number of subjects: 159
Study 21035616 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 159
Study 18586578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling and calcium and vitamin D supplementation
Number of subjects: 0
Study 18586578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16091137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand written signature on covering letter
Number of subjects: 3799
Study 16091137 — intervention group
Group type: COMPARATOR
Intervention: Scanned and printed signature on covering letter
Number of subjects: 3799
Study 16091137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3799
Study 12142585 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week in-hospital physical rehabilitation program supplemented with an exercise-training program (REX, n = 17)
Number of subjects: 31
Study 12142585 — intervention group
Group type: COMPARATOR
Intervention: 12-week home-based physical rehabilitation program without exercise (R, n = 14)
Number of subjects: 31
Study 12142585 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls, nonburn children (NB) aged 7 to <18 (n = 20)
Number of subjects: 31
Study 10206081 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-2213ad 0.3 mg
Number of subjects: 32
Study 10206081 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-2213ad 3 mg
Number of subjects: 32
Study 10206081 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-2213ad 100 mg
Number of subjects: 32
Study 10206081 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-2213ad
Number of subjects: 32
Study 10206081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7794784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure at 5 degrees C
Number of subjects: 30
Study 7794784 — intervention group
Group type: COMPARATOR
Intervention: Control group at 28 degrees C
Number of subjects: 30
Study 2221411 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 2221411 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/halothane
Number of subjects: 20
Study 729626 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 50 mg t.i.d.
Number of subjects: 11
Study 729626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31138224 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30/60 mg once daily (QD)
Number of subjects: 184
Study 31138224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 31138224 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30/60 mg QD
Number of subjects: 184
Study 27485006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB)
Number of subjects: 0
Study 27485006 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl-Cysteine (NAC)
Number of subjects: 0
Study 27485006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25380326 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 angiography-guided endovascular therapy (EVT)
Number of subjects: 98
Study 23519763 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy load (HL; 70% 1RM) resistance exercise
Number of subjects: 0
Study 23519763 — intervention group
Group type: COMPARATOR
Intervention: Light load (LL; 16% 1RM) resistance exercise
Number of subjects: 0
Study 21617451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting enriched with platelet-rich plasma at 10 percent (group A)
Number of subjects: 42
Study 21617451 — intervention group
Group type: COMPARATOR
Intervention: Coleman fat grafting alone (group B)
Number of subjects: 42
Study 19436039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 20
Study 19436039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16960168 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of black (0.1 g), green (0.1 g), and mulberry (1.0 g) teas with carbohydrate-containing meal (50 g carbohydrate as white rice, 10 g butter, and 0.2 g [13C]triolein)
Number of subjects: 0
Study 16960168 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of black, green, and mulberry teas with lipid-containing meal (30 g olive oil and 0.2 g [13C]triolein)
Number of subjects: 0